CryoPort, Inc. (CYRX)

Over the past six months, CryoPort's stock has experienced significant events and positive momentum, with the stock price increasing by 55.23% in the last six months and 31.55% year-to-date as of May 4, 2026. Key events include strong Q1 2026 financial results with a 16% year-over-year revenue increase, raised full-year 2026 revenue guidance, analyst upgrades and price target increases, reaching a new 52-week high, and the reporting of Q4 2025 and Q3 2025 financial results with double-digit revenue growth.

The demand for CryoPort's products and services is driven by the continuous development and commercialization of cell and gene therapies. The pharmaceutical cold-chain logistics market is projected to experience significant growth, indicating sustained and increasing demand rather than strong seasonality. CryoPort's revenue has shown consistent year-over-year growth, suggesting steady demand throughout the year as clinical trials progress and approved therapies gain market penetration.

CryoPort, Inc. is a global leader in integrated temperature-controlled supply chain solutions for the life sciences industry, focusing on the cell and gene therapy market. The company operates in the Healthcare sector, specifically in Biotechnology: Pharmaceutical Preparations, Logistics, and Air Freight/Couriers. CryoPort's business is divided into Life Sciences Services, which includes temperature-controlled logistics, biostorage, and cryopreservation, and Life Sciences Products, which involves manufacturing cryogenic freezers and related accessories. The company serves biopharmaceutical companies, contract manufacturers, contract research organizations, developers, researchers, animal health markets, and human reproductive medicine markets globally.

CryoPort has a strong global presence with 50 strategic locations across the Americas, EMEA, and APAC. The company's global platform provides mission-critical bio-logistics, bio-storage, bio-processing, and cryogenic systems worldwide. Recent expansions include a new Global Supply Chain Hub in Stevenage, U.K., an expanded footprint in Pont-du-Chateau, France, and the launch of a new Global Supply Chain Center in Louvres, France, planned operational expansions in Paris (Q3 2026) and Santa Ana (Q4 2026).

CryoPort maintains a strong brand reputation as a global leader in temperature-controlled supply chain solutions for the life sciences. Positive events contributing to its reputation include ISO 21973 certification, new product launches of advanced MVE vapor shippers, strategic expansions with new Global Supply Chain Hubs, strong financial performance and analyst confidence, and market leadership supporting approximately 70% of the industry's clinical trials in regenerative medicine. No specific negative events significantly impacting CryoPort's brand reputation were found.

CryoPort's stock ownership is a mix of institutional, insider, and retail investors. Institutional investors own approximately 40.34% of the company's stock, with major holders including Morgan Stanley, BlackRock, Inc., and Vanguard Group Inc. Insiders own approximately 3.93%, with CEO Jerrell Shelton being the largest individual shareholder. Retail investors hold approximately 55.73% of CryoPort Inc (CYRX) stock.